JOINN Surges Over 7% Against Market Trend on Strong Q1 Profit and Order Growth

Stock News05-15

JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million.

Recently, JOINN released its first-quarter report for 2026. Revenue reached RMB 316 million, a year-on-year increase of 10.02%. Net profit attributable to shareholders was RMB 238 million, surging approximately 479.67% year-on-year. Basic earnings per share were RMB 0.32.

According to analysis, the company's first-quarter performance met expectations, with newly signed orders more than doubling. Specifically, new orders in the first quarter amounted to RMB 910 million, a year-on-year increase of 111.6%. The backlog of orders at the end of the period stood at RMB 3.1 billion, up 40.9% year-on-year, laying a solid foundation for future performance growth.

The analysis further notes that considering ongoing domestic policies encouraging innovation, coupled with active performance in A+H innovative drug stocks and a recovery trend in IPOs, domestic demand is expected to see marginal improvement in the coming years. As a core participant in China's preclinical CRO business, the company is positioned to benefit significantly from this trend.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106971612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106971612","market":"other","top_or_hot":-1,"title":"JOINN Surges Over 7% Against Market Trend on Strong Q1 Profit and Order Growth","media":"Stock News","content":"<p>JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million.</p>\n<p>Recently, JOINN released its first-quarter report for 2026. Revenue reached RMB 316 million, a year-on-year increase of 10.02%. Net profit attributable to shareholders was RMB 238 million, surging approximately 479.67% year-on-year. Basic earnings per share were RMB 0.32.</p>\n<p>According to analysis, the company's first-quarter performance met expectations, with newly signed orders more than doubling. Specifically, new orders in the first quarter amounted to RMB 910 million, a year-on-year increase of 111.6%. The backlog of orders at the end of the period stood at RMB 3.1 billion, up 40.9% year-on-year, laying a solid foundation for future performance growth.</p>\n<p>The analysis further notes that considering ongoing domestic policies encouraging innovation, coupled with active performance in A+H innovative drug stocks and a recovery trend in IPOs, domestic demand is expected to see marginal improvement in the coming years. As a core participant in China's preclinical CRO business, the company is positioned to benefit significantly from this trend.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JOINN Surges Over 7% Against Market Trend on Strong Q1 Profit and Order Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJOINN Surges Over 7% Against Market Trend on Strong Q1 Profit and Order Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-15 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million.</p>\n<p>Recently, JOINN released its first-quarter report for 2026. Revenue reached RMB 316 million, a year-on-year increase of 10.02%. Net profit attributable to shareholders was RMB 238 million, surging approximately 479.67% year-on-year. Basic earnings per share were RMB 0.32.</p>\n<p>According to analysis, the company's first-quarter performance met expectations, with newly signed orders more than doubling. Specifically, new orders in the first quarter amounted to RMB 910 million, a year-on-year increase of 111.6%. The backlog of orders at the end of the period stood at RMB 3.1 billion, up 40.9% year-on-year, laying a solid foundation for future performance growth.</p>\n<p>The analysis further notes that considering ongoing domestic policies encouraging innovation, coupled with active performance in A+H innovative drug stocks and a recovery trend in IPOs, domestic demand is expected to see marginal improvement in the coming years. As a core participant in China's preclinical CRO business, the company is positioned to benefit significantly from this trend.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603127","symbol_name":"昭衍新药","start_time":0,"source_url":"","article_id":"1106971612","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106971612","pubTimestamp":1778811626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million. Recently, JOINN released its first-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603127":"昭衍新药","BK1141":"生命科学工具和服务","BK0216":"研究试验","BK1576":"医药外包概念","06127":"昭衍新药","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"第一季度利润和订单强劲增长，JOINN逆市飙升逾7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":1,"06127":1,"VXUS":1},"content_text":"JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million.\nRecently, JOINN released its first-quarter report for 2026. Revenue reached RMB 316 million, a year-on-year increase of 10.02%. Net profit attributable to shareholders was RMB 238 million, surging approximately 479.67% year-on-year. Basic earnings per share were RMB 0.32.\nAccording to analysis, the company's first-quarter performance met expectations, with newly signed orders more than doubling. Specifically, new orders in the first quarter amounted to RMB 910 million, a year-on-year increase of 111.6%. The backlog of orders at the end of the period stood at RMB 3.1 billion, up 40.9% year-on-year, laying a solid foundation for future performance growth.\nThe analysis further notes that considering ongoing domestic policies encouraging innovation, coupled with active performance in A+H innovative drug stocks and a recovery trend in IPOs, domestic demand is expected to see marginal improvement in the coming years. As a core participant in China's preclinical CRO business, the company is positioned to benefit significantly from this trend.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106971612","isCrawlerRequest":true}